Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression. This response, although vital for immune defence, is frequently deleterious to the host due to the exaggerated production of inflammatory proteins. The scope of inflammatory responses reflects the activation state of signalling proteins upstream of inflammatory genes as well as signalinduced assembly of nuclear chromatin complexes that support mRNA expression [1] [2] [3] [4] . Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a critical step in the regulation of gene expression [5] [6] [7] [8] [9] [10] . Here we present a novel pharmacological approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins. We describe a synthetic compound (I-BET) that by 'mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteriainduced sepsis. Our findings suggest that synthetic compounds specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.
BET proteins BRD2, BRD3 and BRD4 (hereafter defined as BET) govern the assembly of histone acetylation-dependent chromatin complexes that regulate inflammatory gene expression [5] [6] [7] [8] . This function of BET suggests the possibility of intervention with inflammatory gene expression by disrupting chromatin complexes essential for mRNA transcription, elongation and splicing.
The diversity of binding surfaces, created by differences in sequences surrounding the bromodomain acetyl-binding pocket of BET, and other bromodomain-containing proteins, provided a foundation for selective pharmacological targeting of BET 9, [11] [12] [13] [14] . Using an approach that uses the ability of synthetic compounds to bind selectively to individual proteins in cell lysates (see Supplementary Material), we identified compounds that interact with BET. One of these compounds, GSK525762A (Fig. 1a) , henceforth referred to as I-BET, showed the highest affinity interaction with BET (Fig. 1) . The crystal structure of I-BET bound to BRD4-bromodomain 1 (BD1) showed I-BET positioned at the acetyl-lysine (AcK)-binding pocket ( Fig. 1b and Supplementary Fig. 1a, b) . Hydrogen bonding interactions essential for binding of AcK to asparagine 140 and tyrosine 97 within the bromodomain was mimicked by the triazoyl ring of I-BET (Fig. 1b) . The selectivity of I-BET interaction with BET was determined by the ZA hydrophobic channel and WPF shelf outside of the AcK binding pocket, where a conserved isoleucine or valine impose spatial constraints on the size of molecules that can gain access to the WPF shelf ( Fig. 1b and Supplementary Fig. 1b, c) . Indeed, an enantiomer compound of I-BET (GSK525768A) had no activity towards BET (Fig. 1c, far right panel) . The structural features of I-BET allow two molecules of I-BET to bind to the tandem bromodomains of BET with high affinity (dissociation constant K d of 50.5-61.3 nM; Fig. 1c and Supplementary Fig. 1d, e) . Moreover, I-BET could successfully compete with AcK within the recognition pocket of BET. Fluorescence resonance energy transfer (FRET) analysis demonstrated that I-BET displaced, with high efficacy (half-maximum inhibitory concentration IC 50 of 32.5-42.5 nM), a tetra-acetylated H4 peptide that had been prebound to tandem bromodomains of BET ( Fig. 1d and Supplementary  Fig. 1e ). I-BET is highly selective as it did not interact with other bromodomain-containing proteins from each arm of the phylogeny tree ( Supplementary Fig. 1f ) and had no activity towards a panel of 38 unrelated proteins (Supplementary Table 1) .
Stimulation of bone marrow-derived macrophages (BMDMs) with lipopolysaccharide (LPS) upregulated numerous inflammatory genes (Fig. 2a) . Pre-treatment of BMDMs with I-BET shortly before LPS stimulation resulted in the downregulation of 38 and 151 of the LPSinducible genes at 1 and 4 h, respectively (Fig. 2a, b and Supplementary Table 2 ). I-BET suppressed the expression of key LPS-inducible cytokines and chemokines, including Il6, Ifnb1, Il1b, Il12a, Cxcl9 and Ccl12. The inhibitory effect of I-BET on the expression of the IL-1b processing enzyme Mefv 15 underscored the potential of I-BET to control the IL-1b inflammatory circuit. Furthermore, diminished expression of transcription factors Rel, Irf4 and Irf8 point to the ability of I-BET to curtail the initial wave of inflammatory gene expression ( Fig. 2b and Supplementary Table 2 ). In the absence of LPS stimulation, treatment of BMDMs with I-BET had a marginal effect on gene transcription (Supplementary Fig. 3 Supplementary Fig. 4) . Furthermore, an unaltered pattern of LPS-induced ERK phosphorylation and IkBa degradation in I-BET-treated cells excluded the impact of I-BET on gene expression through dysregulation of Toll-like receptor 4 (TLR4)-dependent signalling ( Supplementary Fig. 5 ). I-BET also had no effect on the expression of housekeeping genes or the viability of BMDMs (Supplementary Figs 4 and 5) . The impact of I-BET on LPS-inducible gene expression is highly selective. The cytokine Tnf as well as chemokines Ccl2-5, Cxcl1/2 were not affected by I-BET (Supplementary Table 2 and Supplementary Fig. 6 ). This specificity and anti-inflammatory potential of I-BET has been validated by the similarity between the effects of I-BET treatment and siRNA-mediated BET knockdown on inflammatory gene expression ( Supplementary  Fig. 7) . Notably, knockdown of BET suppressed the expression of Tnf that was resistant to I-BET ( Supplementary Figs 6 and 7 ). This result points to the existence of BET-recruiting mechanisms that are independent of BET interaction with acetylated histones. The existence of such a mechanism is supported by findings that show recruitment of BET to acetylated Rela or mediator complex 7, 8, 17, 18 . Certain genes were upregulated by I-BET treatment but none of these have a wellestablished role in inflammation (Supplementary Table 2 ). The upregulation of Brd2 and histone-encoding genes (Supplementary Table 2 ) may reflect the existence of a positive feedback mechanism where suppression of BET leads to a compensatory increase in the expression of chromatin proteins. The activating effect of I-BET on gene expression may also reflect the ability of BET to function not only as transcriptional co-activators but also as co-repressors 19 .
The genome-wide analysis of the epigenetic states of LPS-inducible genes that were significantly suppressed or not affected by I-BET (sI-BET and naI-BET genes, respectively) provided a clue for the selective effect of I-BET on gene expression. Elevated basal levels of histone H3 and H4 acetylation (H3ac and H4ac) at the naI-BET gene promoters indicated that naI-BET genes were already primed or actively involved in transcription ( Fig. 3 and Supplementary Fig. 8 ). Indeed, the naI-BET gene promoters were associated with higher basal levels of H3K4me3 and RNA polymerase (Pol) II, including the elongation competent RNA Pol II, phosphorylated at serine 2 (RNA Pol II S2; Fig. 3 ). The important role of the primed/active state in defining the sensitivity to I-BET was underscored by the lack of I-BET effect on expression of housekeeping genes such as Gapdh, Tubb5 and Hprt ( Supplementary  Fig. 4 ) that are characterized by high levels of H3ac, H4ac, H3K4me3 and RNA Pol II at their promoters 5 . Furthermore, an increase in overall histone acetylation levels caused by BMDM treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was able to 'convert' sI-BET into naI-BET genes ( Supplementary Fig. 9 ).
The primed and/or active transcription state of naI-BET genes before LPS stimulation was accomplished without recruitment of significant amounts of BET, thus reducing the likelihood of suppression of these genes by I-BET (Fig. 3) . Furthermore, treatment with I-BET has less impact on BET association with naI-BET compared to sI-BET gene promoters in LPS-treated cells (Fig. 3) . The mechanism of this Gene symbol Gene function phenomenon may reflect higher LPS-induced H3ac and H4ac levels at naI-BET compared to sI-BET gene promoters before and after I-BET treatment ( Fig. 3 and Supplementary Fig. 8 ). Additionally, some of the naI-BET genes may recruit BET via histone acetylation-independent mechanisms 17 . Treatment of BMDMs with I-BET affected not only the promoterbound BET but also the levels of H3ac, H4K5ac, H4K8ac, H4K12ac and total H4ac on LPS-induced gene promoters (Fig. 3 and Supplementary Fig. 8 ). The mechanism of the negative impact of I-BET on histone H3 and H4 acetylation might be twofold. First, by preventing BET from binding to H3ac/H4ac, I-BET increases the accessibility of exposed H3ac/H4ac to HDACs. This model is supported by a nonenzymatic role of BRD4 in H4ac preservation in embryonic stem (ES) cells 20 . It is also possible that I-BET binding to BET prevents the formation of multi-molecular complexes that contain histone acetyltransferases (HATs), other histone modifying enzymes, including lysine H3K4me3 methyltransferases, as well as the positive transcriptional elongation factor b (P-TEFb) and RNA Pol II 7, 8, 18, 19 . This model is consistent with diminished levels of P-TEFb, that contributes to mRNA elongation by RNA Pol II phosphorylation 5, 21, 22 , and reduced amounts of H3K4me3 and RNA Pol II at sI-BET genes (Fig. 3) . The possible direct impact of I-BET on H3ac/H4ac through inhibition of bromodomain-containing HATs was excluded by the inability of I-BET to suppress the activity of the most common HATs such as pCAF, p300, GCN5 and CBP (also known as Kat2b, Ep300, Kat2a and Crebbp, respectively; Supplementary Fig. 10 ).
The features of sI-BET and naI-BET genes assessed by the genomewide analysis were mirrored by the epigenetic states of selected sI-BET 
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and naI-BET genes. Following I-BET treatment, the promoter of the siBET gene Il6 showed a marked reduction in BET recruitment and diminished levels of associated H3K4me3, P-TEFb, RNA Pol II and RNA Pol II S2 (Fig. 3b, c) . In contrast to Il6, the naI-BET gene Tnf showed higher accumulation of BRD2, BRD3 and to a lesser extent BRD4, around the transcriptional start site (TSS) following I-BET treatment (Fig. 3b, c) . The relatively higher BET levels at the Tnf locus were associated with largely unaffected levels of P-TEFb, RNA Pol II and RNA Pol II S2 (Fig. 3b, c) . In support of distinct epigenetic states between sI-BET and naI-BET genes, the sI-BET gene Il1b had reduced BET accumulation at its TSS that resulted in a drop of P-TEFb, Pol II and Pol II S2 levels. In contrast, the epigenetic landscape of the naI-BET gene Nfkbia displayed little change in response to I-BET (Supplementary Fig. 11 ). The selectivity of gene responses to I-BET correlated inversely with the timing of LPS-induced gene activation. Opposite to early stimulated (primary response) naI-BET genes, the majority of sI-BET genes, with the exception of Il1b, belong to the category of secondary response genes (SRG) that become upregulated at later points of macrophage activation ( Supplementary Fig. 12a, c) . Most of the sI-BET genes, as well as Il1b, were characterized by low basal levels of H3ac/H4ac, H3K4me3, RNA Pol II, as well as low CpG content of their promoters (Fig. 3,  Supplementary Figs 8 and 12b) . The latter feature conveys higher stability to promoter-associated nucleosomes that generates a selective barrier for transcriptional activation of secondary response genes 23, 24 . It is likely that suppression of BET recruitment as well as reduction in H3ac/H4ac and H3K4me3 by I-BET aggravates the already nonpermissive transcriptional state of the sI-BET genes and reduces the probability of their expression, thus defining the selectivity of I-BET.
The suppression of key inflammatory genes by I-BET suggested a potent ability of the compound to treat inflammatory conditions in vivo. The serum titres of intravenously (i.v.) administered I-BET remain within the effective concentrations for several hours after injection ( Supplementary Fig. 13 ). Injection of I-BET in mice before the initiation of LPS-or heat-killed Salmonella typhimurium-induced endotoxic shock was able to prevent or attenuate death of mice ( Fig. 4a left and middle panel) . Most promisingly for therapeutic applications, a single dose of I-BET applied at 1.5 h after LPS injection, at the time when mice started to develop symptoms of inflammatory disease, cured the mice (Fig. 4a, left panel) . Furthermore, in mice that suffer from polymicrobial peritonitis and sepsis caused by caecal ligation and puncture (CLP), twice-daily injections of I-BET for 2 days protected mice against death caused by sepsis (Fig. 4a, right panel) .
The marked therapeutic effect of I-BET on endotoxic shock and sepsis occurred despite unaltered serum TNF levels (Fig. 4b) . As TNF is an established mediator of sepsis-associated inflammatory processes, the protective effect of I-BET on sepsis suggests the ability of I-BET to interfere not only with the expression of inflammatory proteins (Fig. 4b ), but also with TNF-inducible gene expression. Indeed, treatment of BMDMs with I-BET suppressed TNF-inducible key pro-inflammatory cytokine (Il1b, Il1a) and chemokine genes (Ccl5, Cxcl10, Cxcl2/3) as well as vasoactive and lipid-related genes (Pdgfb, Adora2b, Fabp3) that contribute to sepsis pathogenesis (Supplementary Fig. 14a, b) . Notably, similar to the sI-BET genes in LPStreated BMDMs, the majority of sI-BET genes in TNF-treated cells fit into the secondary response gene category as assessed by epigenetic modifications and CpG content ( Supplementary Fig. 14c ).
In summary, we show the anti-inflammatory potential of the synthetic compound I-BET that, by interfering with binding of bromodomain-containing BET proteins to acetylated histones, disrupts the formation of the chromatin complexes essential for expression of inflammatory genes. The genes susceptible to I-BET share a common pattern of chromatin modifications at their promoters as well as low promoter CpG content. Suppression of inflammation by I-BET demonstrates the potential of drugs that interfere with protein binding to post-translationally modified histones to achieve a high level of selectivity and potency by exploiting the inherited epigenetic states of genes that contribute to specific physiological and pathological processes.
METHODS SUMMARY
I-BET is an optimized derivative of benzodiazepine compounds that were identified by high-throughput screening of activators of ApoA1-luciferase reporter in HepG2 cells as described in Supplementary Information. The chemical synthesis of I-BET is described in Supplementary Information. The 1.6 Å crystal structure of BRD4-BD1 with I-BET was produced by soaking apo crystals in 2 mM I-BET for 4 days. Molecular replacement using 2oss.pdb gave excellent difference density at the acetylated binding site that allowed the ligand binding to be unambiguously modelled. Methods and statistics for data collection and refined coordinates are provided in Supplementary Information and deposited in the RCSB Protein Data Bank with PDB ID code 3P5O. Bone marrow-derived macrophages (BMDMs) were differentiated from a bone marrow cell suspension obtained from C57BL/6 mice as described in supplementary information. For microarray, qPCR (quantitative PCR) and ChIP (chromatin immunoprecipitation) analyses, BMDMs were pre-incubated with 1 mM or 5 mM of I-BET, DMSO or an inactive I-BET compound for 30 min before LPS (100 ng ml 21 ) or TNF (50 ng ml 21 ) stimulation. Microarray experiments were performed using Illumina MouseRef-8 v2.0 expression BeadChip kits (GEO accession code GSE21764). qPCR was performed using SYBR Green (Roche Lightcycler 480). ChIP was performed as described 25 and detailed in supplementary information. ChIP sequencing libraries were generated as described 26 (GEO accession code GSE21910). For LPS-induced endotoxic shock, 5 mg per kg of LPS was injected intraperitoneally (i.p.) into age-matched C57BL/6 mice. Heat-killed Salmonella typhimurium (IR715; 5 3 10 9 per kg) was injected intravenously. Caecal ligation puncture (CLP) was performed as described 27 . For in vivo experiments I-BET or a solvent control (20% beta-cyclodextrin, 2% DMSO in 0.9% saline) were given via retro-orbital or tail vein injection (CLP) at a dose of 30 mg per kg. 9 per kg, n 5 10 per group) (middle panel); or mice subjected to caecal ligation puncture (CLP) procedure that were administered a solvent control or 30 mg per kg of I-BET twice a day for 2 days (n 5 8 per group) (right panel). b, Serum titres of indicated cytokines were measured by ELISA (n 5 10 per group). Mice received a solvent control (black squares) or I-BET (blue triangles) 1 h before LPS injection and samples were collected at 2 h after LPS treatment. ***P , 0.001, **P , 0.01, *P , 0.05 as determined by unpaired t-test.
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